Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity

Journal of Immunology

Volumn 179, Issue 3, 2007, Pages 1730-1739

  Vrtala, Susanne ^a   Focke, Margarete ^a   Kopec, Jolanta ^c   Verdino, Petra ^c   Hartl, Arnulf ^d   Sperr, Wolfgang R ^b   Fedorov, Alexander A ^f   Ball, Tanja ^f   Almo, Steve ^f   Valent, Peter ^b   Thalhamer, Josef ^e   Keller, Walter ^c   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF SALZBURG   (Austria)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; PHL P 6 ALLERGEN; POLLEN ANTIGEN; UNCLASSIFIED DRUG; ALLERGEN; ANTISERUM; HYBRID PROTEIN; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT; PHLPVI PROTEIN, PHLEUM PRATENSE; VACCINE; VEGETABLE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BASOPHIL; BASOPHIL DEGRANULATION; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG SYNTHESIS; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; GRASS POLLEN; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPARATIVE STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; POLLEN; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; RABBIT; SYNTHESIS;

ALLERGENS; ANIMALS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PHLEUM; PLANT PROTEINS; POLLEN; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINES;

EID: 34548632913     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.3.1730     Document Type: Article

References (60)

1. Kay, A. B. 1997. Allergy and Allergic Diseases. Blackwell Science, Oxford, U.K.
2. Ishizaka, K., T. Ishizaka, and M. M. Hornbrook. 1966. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with γ-E-globulin antibody. J. Immunol. 97: 840-853.
3. Turner, H., and J. P. Kinet. 1999. Signalling through the high-affinity IgE receptor FcεRI. Nature 402: B24-B30.
4. Nadler, M. J., S. A. Matthews, H. Turner, and J. P. Kinet. 2000. Signal transduction by the high-affinity immunoglobulin E receptor FcεRI: coupling form to function. Adv. Immunol. 76: 325-355.
5. Valenta, R. 2002. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2: 446-453.
6. Valenta, R., T. Ball, M. Focke, B. Linhart, N. Mothes, V. Niederberger, S. Spitzauer, I. Swoboda, S. Vrtala, K. Westritschnig, and D. Kraft. 2004. Immunotherapy of allergic disease. Adv. Immunol. 82: 105-153.
7. Moller, C., S. Dreborg, H. A. Ferdousi, S. Halken, A. Host, L. Jacobsen, A. Koivikko, D. Y. Koller, B. Niggemann, L. A. Norberg, et al. 2002. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109: 251-256.
8. Bousquet, J., R. Lockey, and H. J. Malling. 1998. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102: 558-562.
9. Drachenberg, K. J., A. W. Wheeler, P. Stuebner, and F. Horak. 2001. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56: 498-505.
10. Hessel, E. M., M. Chu, J. O. Lizcano, B. Chang, N. Herman, S. A. Kell, M. Wills-Karp, and R. L. Coffman. 2005. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med. 202: 1563-1573.
11. Tighe, H., K. Takabayashi, D. Schwartz, G. Van Nest, S. Tuck, J. J. Eiden, A. Kagey-Sobotka, P. S. Creticos, L. M. Lichtenstein, H. L. Spiegelberg, and E. Raz. 2000. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106: 124-134.
12. Larche, M., and D. C. Wraith. 2005. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11: S69-S76.
13. Singh, M. B., N. de Weerd, and P. L. Bhalla. 1999. Genetically engineered plant allergens with reduced anaphylactic activity. Int. Arch. Allergy Immunol. 119: 75-85.
14. Colombo, P. 2003. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: in vitro and in vivo evaluation. Arb. Paul Ehrlich Inst. Bundesamt Sera Impfstoffe Frankf. A. M. 94: 198-203.
15. Bhalla, P. L., and M. B. Singh. 2004. Engineered allergens for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 4: 569-573.
16. Reese, G., J. Viebranz, S. M. Leong-Kee, M. Plante, I. Lauer, S. Randow, M. S. Moncin, R. Ayuso, S. B. Lehrer, and S. Vieths. 2005. Reduced allergenic potency of VR9-1, a mutant of the major shrimp allergen Pen a 1 (tropomyosin). J. Immunol. 175: 8354-8364.
17. Thomas, W. R., B. J. Hales, and W. A. Smith. 2005. Genetically engineered vaccines. Curr. Allergy Asthma. Rep. 5: 197-203.
18. Muller, U., C. A. Akdis, M. Fricker, M. Akdis, T. Blesken, F. Bettens, and K. Blaser. 1998. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101: 747-754.
19. Haselden, B. M., A. B. Kay, and M. Larche. 2000. Peptide-mediated immune responses in specific immunotherapy. Int. Arch. Allergy Immunol. 122: 229-237.
20. + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in catallergic subjects. Clin. Exp. Allergy 35: 52-58.
21. H2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. 108: 191-197.
22. Santeliz, J. V., G. Van Nest, P. Traquina, E. Larsen, and M. Wills-Karp. 2002. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109: 455-462.
23. Niederberger, V., F. Horak, S. Vrtala, S. Spitzauer, M. T. Krauth, P. Valent, J. Reisinger, M. Pelzmann, B. Hayek, M. Kronqvist, et al. 2004. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14677-14682.
24. Jutel, M., L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell. 2005. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116: 608-613.
25. Gafvelin, G., S. Thunberg, M. Kronqvist, H. Gronlund, R. Gronneberg, M. Troye-Blomberg, M. Akdis, H. Fiebig, A. Purohit, F. Horak, et al. 2005. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol. 138: 59-66.
26. Suphioglu, C. 2000. What are the important allergens in grass pollen that are linked to human allergic disease? Clin. Exp. Allergy 30: 1335-1341.
27. Focke, M., V. Mahler, T. Ball, W. R. Sperr, Y. Majlesi, P. Valent, D. Kraft, and R. Valenta. 2001. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15: 2042-2044.
28. Schramm, G., H. Kahlert, R. Suck, B. Weber, H. T. Stuwe, W. D. Muller, A. Bufe, W. M. Becker, M. W. Schlaak, L. Jager, et al. 1999. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol. 162: 2406-2414.
29. Vrtala, S., S. Fischer, M. Grote, L. Vangelista, A. Pastore, W. R. Sperr, P. Valent, R. Reichelt, D. Kraft, and R. Valenta. 1999. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from timothy grass (Phleum pratense) pollen. J. Immunol. 163: 5489-5496.
30. Matthiesen, F., L. Friberg, M. Olsen, and H. Lowenstein. 1993. Purification and characterization of the Phleum pratense (timothy) pollen allergen Phl p 6. In Molecular Biology and Immunology of Allergens. D. Kraft and A. Sehon, eds. CRC Press, Boca Raton, FL, pp. 189-191.
31. Petersen, A., A. Bufe, G. Schramm, M. Schlaak, and W. M. Becker. 1995. Characterization of the allergen group VI in timothy grass pollen (Phl p 6). II. cDNA cloning of Phl p 6 and structural comparison to grass group V. Int. Arch. Allergy Immunol. 108: 55-59.
32. Fling, S. P., and D. S. Gregerson. 1986. Peptide and protein molecular weight determination by electrophoresis using a high-molarity Tris buffer system without urea. Anal. Biochem. 155: 83-88.
33. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354.
34. Vrtala, S., M. Susani, W. R. Sperr, P. Valent, S. Laffer, C. Dolecek, D. Kraft, and R. Valenta. 1996. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5). J. Allergy Clin. Immunol. 97: 781-787.
35. Valent, P., J. Besemer, M. Muhm, O. Majdic, K. Lechner, and P. Bettelheim. 1989. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc. Natl. Acad. Sci. USA 86: 5542-5546.
36. Vrtala, S., K. Hirtenlehner, L. Vangelista, A. Pastore, H. G. Eichler, W. R. Sperr, P. Valent, C. Ebner, D. Kraft, and R. Valenta. 1997. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99: 1673-1681.
37. Vrtala, S., P. Mayer, F. Ferreira, M. Susani, A. H. Sehon, D. Kraft, and R. Valenta. 1996. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. J. Allergy Clin. Immunol. 98: 913-921.
38. Vrtala, S., T. Ball, S. Spitzauer, B. Pandjaitan, C. Suphioglu, B. Knox, W. R. Sperr, P. Valent, D. Kraft, and R. Valenta. 1998. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J. Immunol. 160: 6137-6144.
39. Westritschnig, K., M. Focke, P. Verdino, W. Goessler, W. Keller, A. Twardosz, A. Mari, F. Horak, U. Wiedermann, A. Hartl, et al. 2004. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol. 172: 5684-5692.
40. Lobley, A., L. Whitmore, and B. A. Wallace. 2002. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18: 211-212.
41. Whitmore, L., and B. A. Wallace. 2004. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32: W668-W673.
42. Harris, N. L., S. R. Presnell, and F. E. Cohen. 1994. Four helix bundle diversity in globular proteins. J. Mol. Biol. 236: 1356-1368.
43. Krissinel, E., and K. Henrick. 2004. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60: 2256-2268.
44. Esch, R. E. 2004. Grass pollen allergens. In Allergens and Allergen Immunotherapy. Marcel Dekker, New York, p. 185.
45. Laffer, S., S. Spitzauer, M. Susani, H. Pairleitner, C. Schweiger, H. Gronlund, G. Menz, G. Pauli, T. Ishii, H. Nolte, et al. 1996. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J. Allergy Clin. Immunol. 98: 652-658.
46. Niederberger, V., S. Laffer, R. Froschl, D. Kraft, H. Rumpold, S. Kapiotis, R. Valenta, and S. Spitzauer. 1998. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J. Allergy Clin. Immunol. 101: 258-264.
47. Heiss, S., V. Mahler, R. Steiner, S. Spitzauer, C. Schweiger, D. Kraft, and R. Valenta. 1999. Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing. J. Invest. Dermatol. 113: 830-837.
48. Niederberger, V., P. Stubner, S. Spitzauer, D. Kraft, R. Valenta, K. Ehrenberger, and F. Horak. 2001. Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. J. Invest. Dermatol. 117: 848-851.
49. Rossi, R. E., G. Monasterolo, and S. Monasterolo. 2001. Measurement of IgE antibodies against purified grass-pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen. Allergy 56: 1180-1185.
50. Westritschnig, K., E. Sibanda, W. Thomas, H. Auer, H. Aspock, G. Pittner, S. Vrtala, S. Spitzauer, D. Kraft, and R. Valenta. 2003. Analysis of the sensitization profile towards allergens in central Africa. Clin. Exp. Allergy 33: 22-27.
51. Mari, A. 2003. Skin test with a timothy grass (Phleum pratense) pollen extract vs. IgE to a timothy extract vs. IgE to rPhl p 1, rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, and rPhl p 12: epidemiological and diagnostic data. Clin. Exp. Allergy 33: 43-51.
52. Moverare, R., T. Petays, E. Vartiainen, and T. Haahtela. 2005. IgE reactivity pattern to timothy and birch pollen allergens in Finnish and Russian Karelia. Int. Arch. Allergy Immunol. 136: 33-38.
53. Valenta, R., and D. Kraft. 2001. Recombinant allergen molecules: tools to study effector cell activation. Immunol. Rev. 179: 119-127.
54. Vrtala, S., K. Hirtenlehner, M. Susani, M. Akdis, F. Kussebi, C. A. Akdis, K. Blaser, P. Hufnagl, B. R. Binder, A. Politou, et al. 2001. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 15: 2045-2047.
55. Reisinger, J., F. Horak, G. Pauli, M. van Hage, O. Cromwell, F. Konig, R. Valenta, and V. Niederberger. 2005. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116: 347-354.
56. Mahler, V., S. Vrtala, O. Kuss, T. L. Diepgen, R. Suck, O. Cromwell, H. Fiebig, A. Hartl, J. Thalhamer, G. Schuler, et al. 2004. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 34: 115-122.
57. Vrtala, S., C. A. Akdis, F. Budak, M. Akdis, K. Blaser, D. Kraft, and R. Valenta. 2000. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol. 165: 6653-6659.
58. Linhart, B., B. Jahn-Schmid, P. Verdino, W. Keller, C. Ebner, D. Kraft, and R. Valenta. 2002. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. 16: 1301-1303.
59. Linhart, B., and R. Valenta. 2004. Vaccine engineering improved by hybrid technology. Int. Arch. Allergy Immunol. 134: 324-331.
60. Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M. T. Krauth, P. Valent, F. Horak, U. Wiedermann, J. Thalhamer, et al. 2005. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115: 1010-1016.